ArticleOchsner journal2013
Cancer stem cell and stromal microenvironment.
Article in Ochsner journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy.Annals of hematology · 2026Review
- Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.International journal of molecular sciences · 2024Review
- Mesenchymal Stem-Like Cells Derived from the Ventricle More Effectively Enhance Invasiveness of Glioblastoma Than Those Derived from the Tumor.Yonsei medical journal · 2023Article
- Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.Journal for immunotherapy of cancer · 2022Review
- The role of mouse models in colorectal cancer research-The need and the importance of the orthotopic models.Animal models and experimental medicine · 2020Review
- Targeting cancer stem cell pathways for cancer therapy.Signal transduction and targeted therapy · 2020Review
- Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization.Frontiers in oncology · 2020Review
- Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties.Oncogene · 2018Article
- Targeting Cancer Stem Cells-A Renewed Therapeutic Paradigm.Oncology & hematology review · 2017Article
- SporadicCancer cell international · 2017Article
- miR-367 stimulates Wnt cascade activation through degrading FBXW7 in NSCLC stem cells.Cell cycle (Georgetown, Tex.) · 2017Article
- The cytokine-cosmc signaling axis upregulates the tumor-associated carbohydrate antigen Tn.Oncotarget · 2016Article
- G9a/RelB regulates self-renewal and function of colon-cancer-initiating cells by silencing Let-7b and activating the K-RAS/β-catenin pathway.Nature cell biology · 2016Article
- Towards Organs on Demand: Breakthroughs and Challenges in Models of Organogenesis.Current pathobiology reports · 2016Article
- Tumor Mesenchymal Stem-Like Cell as a Prognostic Marker in Primary Glioblastoma.Stem cells international · 2016Article
- Cancer Stem Cell and Gastrointestinal Cancer: Current Status, Targeted Therapy and Future Implications.Biochemistry & pharmacology : open access · 2016Article
- Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.Medicinal research reviews · 2015Review
- The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Nanopreparations to overcome multidrug resistance in cancer.Advanced drug delivery reviews · 2013Review
- Letters to the editor.Ochsner journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundChemotherapeutic resistance and local recurrence or distant organ metastasis are the major causes of cancer mortality. Conventional cancer treatments do not consistently prevent cancer recurrence.
methodsWe illustrate the key roles that cancer stem cells and the tumor microenvironment-particularly the lymph node stromal microenvironment-play in tumor drug resistance, metastasis, and recurrence in 2 representative cancers: colorectal cancer and follicular lymphoma.
conclusionWe believe that combination treatment with chemotherapeutic agents in conjunction with targeted therapies, such as stromal/cancer stem cell signaling-targeted therapy, may effectively minimize cancer recurrence.
Indexed as
Identifiers
23531695PMC3603173W2145001877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.